ArticleCancer medicine2025
TWEAK/Fn14 Drives Tumor Progression and Is Associated With Poor Survival of Colorectal Liver Metastases With Replacement Growth Patterns.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Reduced type 2 epithelial-mesenchymal transition serves as a risk factor for the progression from endometriosis to endometriosis-associated ovarian cancer.Scientific reports · 2026Article
- Encapsulated histopathological growth pattern of colorectal liver metastases predicts prolonged survival after repeat liver resection for recurrence.Clinical & experimental metastasis · 2026Article
- TWEAK/Fn14 Drives Tumor Progression and Is Associated With Poor Survival of Colorectal Liver Metastases With Replacement Growth Patterns.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveColorectal liver metastases (CRLMs) with replacement growth pattern (rHGP) are associated with a poor prognosis; however, the underlying mechanisms driving rHGP remain poorly understood. This study investigated the effect of the TWEAK/Fn14 axis in CRLMs on tumor progression to explore the pathology of CRLMs with rHGP.
methodIn total, 129 patients with CRLMs who underwent curative resection were investigated.
resultsPatients with rHGP had significantly poor overall survival after surgery than those with other growth patterns. CRLMs with rHGP exhibited epithelial-mesenchymal transition (EMT) activation and a distinct immune microenvironment. We focused on TWEAK/Fn14 axis to clarify the mechanism by which the tumor microenvironment affects tumor progression in CRLMs with rHGP. TWEAK was expressed in the tumor microenvironment, accompanied by the infiltration of Th17 cells and M2 macrophages, whereas Fn14 was expressed in cancer cells within CRLMs. High TWEAK/high Fn14 expression in CRLMs was more frequently observed in CRLMs with rHGP and was associated with a worse prognosis. This was accompanied by high grade of tumor budding and poorly differentiated clusters in CRLMs, and increased risk of extrahepatic metastases. In vitro, recombinant TWEAK (100 ng/mL) induced phosphorylation of IκB and NFκB (p65) and also enhanced cell migration, invasion, and EMT maker expression in colorectal cancer cells. Cell migration and invasion enhanced by recombinant TWEAK were suppressed by an Fn14 antagonist (ITEM-4: 200 ng/mL). DISCUSSION: This study clarified that the TWEAK/Fn14 axis in CRLMs promotes invasiveness and metastatic potential, leading to poor prognosis. It may be crucial in the adverse survival outcomes of CRLMs with rHGP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.